Role of Cytokines in Allergic Airway InflammationNakajima H.a · Takatsu K.b
aDepartment of Molecular Genetics, Graduate School of Medicine, Chiba University, Chiba, and bDivision of Immunology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan Corresponding Author
Correspondence to: Dr. Hiroshi Nakajima
Department of Molecular Genetics, Graduate School of Medicine
Chiba University 1-8-1 Inohana
Chiba City, Chiba 260-8670 (Japan)
Tel. +81 43 226 2197, Fax +81 43 226 2199, E-Mail email@example.com
Asthma is characterized by intense infiltration of eosinophils and CD4+ T cells into the submucosal tissue of airways. Accumulating evidence indicates that T helper type 2 cell-derived cytokines such as interleukin (IL)-4, IL-5 and IL-13 play critical roles in orchestrating and amplifying allergic inflammation in asthma. In addition, it has been suggested that newly identified cytokines including thymic stromal lymphopoietin, IL-25 and IL-33 are involved in the induction of allergic inflammation in asthma. In this review, we discuss the role of individual cytokines in the pathogenesis of asthma.
© 2007 S. Karger AG, Basel
Immediate hypersensitivity allergic reactions are dependent on degranulation of activated mast cells and peak within 30 min. Over the subsequent several hours, the late-phase allergic reaction (LAR) evolves, peaks at 6–12 h and may persist for several days. In contrast to the immediate hypersensitivity reaction in which histologic findings are predominantly edema and vasodilatation, the LAR is characterized by a prominent leukocytic infiltrate comprised of eosinophils, T helper (Th) 2 cells and neutrophils [1,2,3].
Asthma is a common respiratory disorder characterized by recurrent episodes of coughing, breathlessness and wheezing. It is well established that a strong correlation exists between the presence of eosinophils and the presence of Th2 cells in the asthmatic airways and that classical Th2 cell-derived cytokines, namely interleukin (IL)-4, IL-5, IL-9 and IL-13, play critical roles in orchestrating and amplifying allergic inflammation in asthma. However, accumulating evidence suggests that the regulation of allergic inflammation is more complex. This review will explore our current understanding of the role of individual cytokines in the pathogenesis of asthma with a particular focus on nonclassical cytokines in the mechanism underlying allergic airway inflammation.
Allergic diseases including asthma are characterized by inflammation with pronounced infiltration of eosinophils [1,2,3]. An essential biological activity of IL-4 in the development of allergic inflammation is to drive the differentiation of naive Th0 cells into Th2 cells, which secrete IL-4, IL-5, IL-9 and IL-13 but not interferon (IFN)-γ [4, 5]. Studies using IL-4-deficient mice clearly showed that IL-4 was required for the development of allergic inflammation, as antigen-induced allergic inflammation was significantly decreased in IL-4-deficient mice as compared with wild-type mice . Coyle et al.  also demonstrated that the administration of neutralizing anti-IL-4 antibody prior to antigen immunization prevented the development of antigen-induced airway inflammation, whereas the administration of the same antibody after immunization but prior to antigen inhalation was not effective for preventing antigen-induced airway inflammation. These studies suggest that while IL-4 is essential for the initial differentiation and/or expansion of antigen-specific Th2 cells, IL-4 may not be essential for the induction of allergic airway inflammation at an effector phase. On the other hand, some studies have indicated the importance of IL-4 in promoting allergic inflammation at an effector phase by inducing the recruitment of Th2 cells in part via vascular cell adhesion molecule-1/very late antigen-4-dependent mechanisms [8, 9]. In addition, a clinical trial of soluble IL-4 receptor (IL-4R) that neutralizes IL-4 function showed the therapeutic benefit in moderately severe asthma . Therefore, IL-4 could play a role in the induction of allergic inflammation in a sensitized individual, but the relative importance of IL-4 depends on the state of sensitization and/or genetic background.
IL-5 has been originally defined as a T cell-derived cytokine that triggers activated B cells for a terminal differentiation into immunoglobulin-producing cells . Concurrently, IL-5 has been recognized as the major maturation and differentiation factor for eosinophils [12, 13]. It has been demonstrated that the expression of IL-5 mRNA in bronchial biopsies of asthmatic patients is increased as compared with healthy volunteers and that the predominant source of IL-5 mRNA is CD4+ T cells . Indeed, CD4+ T cell activation in asthma is accompanied by increased serum concentrations of IL-5 . IL-5 mRNA and protein are also found in mast cells located within allergen-challenged tissues. Based on these observations, an attractive paradigm for eosinophil involvement in the LAR is (1) the upregulation of IL-5 synthesis by mast cells activated in an immediate hypersensitivity allergic reaction, resulting in (2) eosinophil recruitment and activation [1,2,3]. Concomitantly, (3) CD4+ T cells are recruited by other inflammatory mediators of the allergic reaction and undergo antigen-specific activation and acquisition of the Th2 phenotype which (4) further enhances eosinophil recruitment and activation.
Animal models further support a role for IL-5 in the induction of eosinophilic inflammation in allergies and asthma. It has been shown that the enforced expression of IL-5 by transgene causes eosinophilia [16,17,18]. A pivotal role for IL-5 in the late asthmatic response has been confirmed by the capacity for neutralizing anti-IL-5 monoclonal antibody (mAb) to inhibit antigen-induced airway hyperresponsiveness and eosinophil infiltration in the airways of mice and guinea pigs [19,20,21]. Importantly, administration of neutralizing anti-IL-5 mAb reduced airway eosinophilia when administered within hours preceding respiratory antigen challenge or when administered up to 5 days after antigen challenge. The lack of bronchial hyperreactivity and eosinophilia in the lungs of antigen-sensitized and antigen-challenged IL-5-deficient and IL-5R α chain (IL-5Rα)-deficient mice further demonstrated the importance of IL-5 in allergic airway inflammation [22,23,24,25].
Results of humanized anti-IL-5 mAb treatment in patients with mild asthma confirmed the importance of IL-5 in eosinophilic inflammation in human . However, anti-IL-5 antibody did not reduce asthmatic symptoms and airway reactivity , suggesting that airway hyperresponsiveness occurs independently of IL-5 and airway eosinophilia. Recently, the role of IL-5 and eosinophils in the development of airway remodeling, in an experimental model of chronic asthma, has been carefully studied by using mice lacking IL-5Rα or mice transgenic for IL-5 . The study has demonstrated that IL-5 plays an obligatory role in the airway remodeling observed in experimental asthma . Intriguingly, treatment of wild-type mice with anti-IL-5 antibody almost completely prevented subepithelial and peribronchial fibrosis caused by antigen inhalation . Importantly, anti-IL-5 antibody treatment has also been shown to improve airway remodeling in asthmatic patients [28, 29]. Further studies are required to define the mechanism underlying IL-5 and eosinophil-mediated airway remodeling in asthma. It may be worthwhile to test the feasibility of humanized anti-IL-5Rα antibody in a monkey asthma model for eliminating eosinophils localized in the airways by antibody-dependent cell-mediated cytotoxicity.
Accumulating evidence suggests that IL-13 plays a key role in the allergic response via its actions on epithelial and smooth muscle cells and not through traditional effector pathways involving eosinophils and immunoglobulin E (IgE)-mediated events [30,31,32]. The importance of IL-13 was evidenced by the finding that neutralization of endogenously released IL-13 with a soluble form of IL-13Rα2, which binds IL-13 but not IL-4, during antigen exposure largely inhibited the characteristics of asthma in murine asthma models [33, 34]. In addition, antigen challenge of IL-13-deficient mice failed to elicit airway hyperresponsiveness and mucus production despite the continued presence of IL-4 and IL-5 and airway inflammation . Its importance as an effector molecule in asthma was further evidenced by the finding that acute administration of IL-13 itself was sufficient to recapitulate many features of airway responses characterized in asthma, such as eosinophilic inflammation, mucus hyperproduction and airway hyperresponsiveness in mice [33, 34]. Moreover, lung-specific expression of IL-13 resulted in the development of characteristic features of asthma . These results suggest that IL-13, independent from other Th2 cytokines, is necessary and sufficient to induce key features of allergic inflammation at an effector phase. Importance of IL-13 in asthma was also supported by strong associations between genetic polymorphisms in the IL-13 gene and asthma . The role of IL-13 in the pathogenesis of asthma has been described in more detail in recent reviews [30,31,32].
Another Th2 cell-derived cytokine that seems involved in the pathogenesis of asthma is IL-9 . First, genetic analyses revealed the possible involvement of IL-9 in causing airway hyperresponsiveness . In addition, it has been demonstrated that the expression of IL-9 is increased in bronchial biopsy samples of asthmatics . Lung-specific overexpression of IL-9 by transgene has also been shown to induce airway hyperresponsiveness in addition to morphological changes that bear similarities to asthma . Neutralizing antibodies against IL-9 further demonstrate a crucial role for IL-9 in the development of the allergic asthmatic response . On the other hand, although IL-9 plays a role in goblet cell hyperplasia and mast cell development, experiments analyzing IL-9-deficient mice show that it has little or no effect on eosinophils, T cell development or immunoglobulin response . Further study is required for clarifying the role of IL-9 in the regulation of allergic airway inflammation.
IFN-γ, the principal Th1 effector cytokine, has been shown to be crucial for the resolution of allergic inflammation. Using murine asthma models, IFN-γ has been shown to prevent the development of antigen-induced airway eosinophilia and hyperresponsiveness [44, 45]. It has also been shown that IFN-γ receptor (IFN-γR)-deficient mice exhibit a prolonged airway eosinophilia in response to allergen inhalation . In accordance with these findings, we found that mice lacking T-bet, the master regulator of Th1 cell development and IFN-γ production , exhibited enhanced antigen-induced allergic airway inflammation [Fujiwara et al., submitted]. These results suggest that IFN-γ could counterbalance Th2 cell-mediated allergic airway inflammation. On the other hand, some studies have shown that the coexistence of Th1 cells aggravates the Th2 cell-mediated allergic responses [47,48,49]. Using cell transfer experiments, it has been shown that allergen-specific Th1 cells enhance Th2 cell-mediated asthmatic airway responses [47,48,49], presumably by inducing the production of tumor necrosis factor (TNF)-α and subsequent vascular cell adhesion molecule-1 expression at the inflamed site . Because IFN-γ itself potently inhibits Th2 cell activation [4, 5] and allergic airway inflammation [44, 45], it is suggested that the balance between IFN-γ and TNF-α produced by activated Th1 cells may be a key determinant of the role of Th1 cells in the regulation of allergic airway inflammation.
IL-12 is produced by antigen-presenting cells such as dendritic cells (DCs) and macrophages and is known to play an important role in Th1 differentiation during primary antigen presentation . In asthmatic individuals, it has been shown that IL-12 expression is reduced in bronchial biopsy samples . In addition, murine asthma models have confirmed that exogenous administration of IL-12 during the primary sensitization suppresses allergen-induced Th2 development and subsequent allergic inflammation . Interestingly, even when IL-12 is administered only during antigen challenge, IL-12 retains the capacity to inhibit allergen-induced allergic inflammation and airway hyperresponsiveness [52, 53]. Because fully differentiated Th2 cells have been shown to lose IL-12 responsiveness , a reversal of Th2 cells towards a Th1 phenotype at this stage seems unlikely. IL-12 may suppress Th2 cell-mediated allergic inflammation by augmenting the production of IFN-γ from coexisting Th1 cells, CD8+ T cells or natural killer cells.
IL-18 was initially described as IFN-γ-releasing factor . Consistent with this finding, the absence of endogenous IL-18 in IL-18-deficient mice resulted in enhanced antigen-induced airway eosinophilia . In addition, IL-12 and IL-18 act synergistically in inducing IFN-γ production and inhibit IL-4-dependent IgE synthesis and allergen-induced airway hyperresponsiveness . These results suggest that IL-18 functions as a negative regulator for allergic inflammation. On the other hand, it has recently been shown that Th1 cells come to produce a large amount of Th2 cytokines such as IL-9 and IL-13 and robust IFN-γ and TNF-α when stimulated with antigen plus IL-18, while Th1 cells do not produce IL-9 and IL-13 and produce less amounts of IFN-γ and TNF-α when stimulated with antigen in the absence of IL-18 . Moreover, when Th1 cell-transferred mice are challenged with antigen and IL-18, mice develop severe airway inflammation characterized by massive infiltration of eosinophils as in the antigen-challenged Th2 cell-transferred mice . Furthermore, we have demonstrated that the administration of IL-18 enhances antigen-induced eosinophil recruitment into the airways of sensitized mice in part by increasing antigen-induced TNF-α production . Thus, it is suggested that the function of IL-18 depends on the environmental cytokines . Further study is needed to address the molecular basis for the pleiotrophic function of IL-18.
IL-27, an IL-12-related cytokine with pro- and anti-inflammatory properties, is composed of p28 subunit and EBI3 . The cells responsible for IL-27 production are DCs and macrophages . IL-27R is composed of gp130 and WSX1, which was known as an orphan receptor that induces Th1 cell differentiation . An early study has indicated that IL-27 functions as a proinflammatory cytokine because it synergizes with IL-12 to promote Th1 responses . Th1 deviation by IL-27 is due in part to the induction of T-bet . A recent study has also shown that addition of IL-27 to naive T cells under Th2-polarizing conditions decreases the expression of GATA-3, a master regulator for Th2 development, and thus IL-4 production . Consistent with these findings, ovalbumin-challenged WSX1-deficient mice showed a marked enhancement of Th2 cytokine production, eosinophil infiltration into the airway, and airway hyperresponsiveness with goblet cell hyperplasia , suggesting that IL-27 functions as a negative regulator of Th2-type immune responses in vivo. Interestingly, IFN-γ production was also enhanced in WSX1-deficient mice . Therefore, these results suggest that the enhanced allergic responses in WSX1-deficient mice seem to be independent from the Th1-promoting property of IL-27.
The original member of the IL-17 family, IL-17A, was identified in 1995, and subsequently, 5 cytokines, IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25) and IL-17F, were identified as IL-17 family cytokines . IL-17A and IL-17F are mainly expressed in a recently identified subpopulation of CD4+ T cells, namely Th17 cells, which are believed to be involved in the pathogenesis of autoimmune diseases . Both IL-17A and IL-17F induce the expression of a variety of cytokines and chemokines including IL-6, granulocyte macrophage colony-stimulating factor and CXCL10 from epithelial and vascular endothelial cells and induce IL-8 from fibroblasts [65, 67, 68]. The ability of IL-17A and IL-17F to evoke migration of neutrophils but not of eosinophils makes it likely that these cytokines are involved in severe asthma, in which accumulation of neutrophils in the airways is a hallmark of disease . Because IL-17 and IL-17F are expressed in the airway of asthmatic patients , these cytokines may constitute a link between the activation of T cells and recruitment of neutrophils into the airways.
IL-25 is produced by activated Th2 cells  and mast cells . The in vivo and in vitro biological activities of IL-25 are markedly different from those described for IL-17 and other IL-17 family cytokines [65, 70, 72, 73]. Systemic administration of IL-25 protein  or the systemic expression of IL-25 by transgene  induces the production of IL-4, IL-5 and IL-13 from undefined non-T/non-B cells and the resultant Th2-type immune responses including blood eosinophilia, increased serum IgE levels and pathological changes in the lung and other tissues. We also found that IL-25 mRNA was expressed in the lung upon antigen inhalation and that neutralization of endogenously produced IL-25 by soluble IL-25R decreased antigen-induced eosinophil and CD4+ T cell recruitment into the airways . In addition, we found that although the enforced expression of IL-25 in the lung itself failed to induce allergic airway inflammation, the expression of IL-25 significantly enhanced antigen-induced eosinophil and Th2 cell recruitment in the airways . Moreover, IL-25-induced enhancement of antigen-induced eosinophil recruitment into the airways was inhibited by the depletion of CD4+ T cells . These findings indicate that IL-25 plays an important role in enhancing antigen-induced allergic airway inflammation by amplifying a Th2 cell-dependent pathway. Furthermore, the enhanced expression of IL-25 in the airway of asthmatic patients has been recently reported . These findings raise the possibility that IL-25 may be involved in the enhancement and/or prolongation of Th2 cell-mediated allergic inflammation in asthma and suggest that IL-25 could be a possible target of allergic diseases.
The proinflammatory activities of TNF-α including leukocyte recruitment through the upregulation of adhesion molecules on endothelial cells and induction of cytokine and chemokine synthesis seem involved in the pathogenesis of asthma . Elevated levels of TNF-α have been detected in bronchoalveolar lavage fluid and biopsy samples in asthmatic patients . Inhalation of TNF-α also causes airway hyperresponsiveness and an increase in sputum neutrophil counts in healthy volunteers . On the other hand, it has been shown that pretreatment with anti-TNF-α antibodies profoundly reduces the endotoxin or IL-18-induced airway changes in a rodent model [59, 79]. More recently, treatment with TNF-α antagonist etanercept has been shown to reduce airway hyperreactivity and asthma symptoms , suggesting the in vivo relevance of TNF-α in the pathogenesis of severe asthma.
Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine that may trigger Th2-type inflammation . TSLP is highly expressed in skin keratinocytes and airway epithelial cells during allergic inflammation . Functional TSLP receptor (TSLPR) consists of TSLPR and IL-7Rα chain [82, 83]. TSLP induces the maturation of DCs, especially the induction of OX40L, without driving the production of the Th1-polarizing cytokine such as IL-12 . Consequently, TSLP-stimulated DCs trigger Th2 polarization, promote TNF-α production and inhibit IL-10 production . The resultant Th2 cells that produce high levels of TNF-α but little IL-10 may be more potent in inducing allergic inflammation than conventional Th2 cells. In addition, TSLP-stimulated DCs have recently been shown to induce a robust expansion and further polarization of Th2 memory cells . Moreover, TSLP-stimulated DCs produce a number of chemokines which may participate in the recruitment of neutrophils, eosinophils and Th2 cells into the site of allergic inflammation . Indeed, lung-specific expression of TSLP by transgene results in airway inflammation and hyperreactivity . Furthermore, it has been demonstrated that TSLP expression is increased in the lungs of sensitized mice upon antigen inhalation  and that TSLPR-deficient mice exhibit attenuated responses to the inhaled antigen [86, 87]. A recent study has also shown that TSLP expression is increased in asthmatic airway in humans and is correlated with the expression of Th2 cell-attracting chemokines and disease severity . These findings suggest that TSLP is involved in the induction of airway inflammation in asthma and that TSLP is a possible target for immunological intervention in the treatment of allergic diseases.
IL-21 is a product of activated CD4+ T cells, and IL-21R consists of IL-21Rα and common cytokine receptor γ chain . Recent studies indicate that IL-21 is involved in the downregulation of IgE production [90,91,92]. Naive IL-21Rα-deficient mice showed a considerably higher serum concentration of IgE than wild-type mice [90, 91]. Interestingly, immunization of IL-21Rα-deficient mice with ovalbumin or keyhole limpet hemocyanin results in higher levels of IgE compared with wild-type mice, without affecting IL-4 production . In accordance with these findings, administration of recombinant IL-21 decreases antigen-specific IgE production and attenuates antigen-induced eosinophil recruitment into the airways in sensitized mice . These effects of IL-21 on IgE production and eosinophil recruitment into the airways in an asthma model indicate that IL-21 might have an important regulatory role in airway responses to antigens and suggest that increasing the levels of IL-21 might be of value for treating allergic diseases, such as asthma. On the other hand, it has recently been demonstrated that IL-21 inhibits IFN-γ production in developing Th1 cells by repressing the expression of a T-bet-related transcription factor eomesodermin , suggesting that IL-21 may have diverse roles in the regulation of allergic airway inflammation.
IL-31 seems most closely related to oncostatin M, leukemia inhibitory factor and cardiotrophin-1 and is expressed in activated CD4+ T cells, with the highest levels found in T cells activated in Th2-polarizing conditions . IL-31 induces the expression of a large number of chemokines without altering cytokine levels , suggesting that IL-31 is involved in the recruitment of inflammatory cells to the sites. Indeed, mice expressing IL-31 in skin showed an increase in the number of lesions with an inflammatory cell infiltrate similar to that observed in atopic dermatitis . In addition, it has been demonstrated that activated leukocytes in patients with atopic dermatitis expressed significantly higher IL-31 levels as compared with control subjects [95, 96]. The possible involvement of IL-31 in allergic airway inflammation warrants further investigation in light of these early findings.
ST2 is an IL-1R-related protein expressed on Th2 cells and mast cells . ST2 has been shown to function as an important effector molecule of Th2 responses in a number of experimental settings including mouse asthma models [98,99,100]. Recently, an IL-1-like cytokine, IL-33, has been identified as a ligand for ST2 . It has been demonstrated that IL-33 is produced by many cell types including smooth muscle cells, epithelial cells and DCs and drives production of IL-5 and IL-13 from in vitro polarized Th2 cells . These findings suggest that IL-33/ST2 interaction may play a significant role in the induction of allergic airway inflammation.
There is overwhelming evidence to support a major role for T cells, especially Th2 cells, and their cytokines in asthma (fig. 1). In addition to classical Th2 cytokines such as IL-4, IL-5, IL-9 and IL-13, other cytokines derived from Th2 cells, including IL-25 and IL-31, have also been shown to play an important role in causing allergic inflammation. Non-lymphoid cell-derived cytokines such as IL-33 and TSLP are also involved in the induction of allergic inflammation through the induction of Th2 cell differentiation. Further studies identifying relative importance of these cytokines in asthmatic patients are needed to uncover therapeutic targets for asthma.
Correspondence to: Dr. Hiroshi Nakajima
Department of Molecular Genetics, Graduate School of Medicine
Chiba University 1-8-1 Inohana
Chiba City, Chiba 260-8670 (Japan)
Tel. +81 43 226 2197, Fax +81 43 226 2199, E-Mail firstname.lastname@example.org
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.